3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
334
Carcinoma, Renal Cell
112
Urinary Bladder Neoplasms
95
Breast Neoplasms
55
Carcinoma, Transitional Cell
52
Colorectal Neoplasms
43
Carcinoma, Non-Small-Cell Lung
42
Melanoma
41
Ovarian Neoplasms
39
Kidney Neoplasms
39
Neoplasms
38
Neoplasm Metastasis
31
Lung Neoplasms
28
Sarcoma
26
Non-Muscle Invasive Bladder Neoplasms
26
Uterine Cervical Neoplasms
25
Pancreatic Neoplasms
24
Endometrial Neoplasms
23
Stomach Neoplasms
22
Wilms Tumor
19
Squamous Cell Carcinoma of Head and Neck
19
Carcinoma, Hepatocellular
19
Esophageal Neoplasms
18
Adenocarcinoma
18
Triple Negative Breast Neoplasms
17
Head and Neck Neoplasms
17
Small Cell Lung Carcinoma
15
Thyroid Neoplasms
14
Metastatic Castration-resistant Prostate Cancer
14
Neuroblastoma
13
Interventions
BCG Vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma in Situ
×
Genitourinary
×
30 days
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled
NCT05951179
2026-05-18
ADVANCED-2
Protara Therapeutics
Phase 2
Recruiting
131 enrolled